CLINICAL TRIALS PROFILE FOR TIOPRONIN

All Clinical Trials for tiopronin

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01095731 ↗	The Effects of Tiopronin on 3-Aminopropanal Level & Neurologic Outcome After Aneurysmal Subarachnoid Hemorrhage	Completed	Food and Drug Administration (FDA)	Phase 2	2010-04-01	The purpose of this phase II study is to further assess the safety of tiopronin in aneurysmal subarachnoid hemorrhage(aSAH) patients in order to obtain preliminary data on the efficacy of tiopronin versus placebo in reducing serum and cerebrospinal fluid (CSF) 3AP levels in this patient population. Funding Source - FDA Office of Orphan Products Development
NCT01095731 ↗	The Effects of Tiopronin on 3-Aminopropanal Level & Neurologic Outcome After Aneurysmal Subarachnoid Hemorrhage	Completed	University of Florida	Phase 2	2010-04-01	The purpose of this phase II study is to further assess the safety of tiopronin in aneurysmal subarachnoid hemorrhage(aSAH) patients in order to obtain preliminary data on the efficacy of tiopronin versus placebo in reducing serum and cerebrospinal fluid (CSF) 3AP levels in this patient population. Funding Source - FDA Office of Orphan Products Development
NCT01095731 ↗	The Effects of Tiopronin on 3-Aminopropanal Level & Neurologic Outcome After Aneurysmal Subarachnoid Hemorrhage	Completed	University of Washington	Phase 2	2010-04-01	The purpose of this phase II study is to further assess the safety of tiopronin in aneurysmal subarachnoid hemorrhage(aSAH) patients in order to obtain preliminary data on the efficacy of tiopronin versus placebo in reducing serum and cerebrospinal fluid (CSF) 3AP levels in this patient population. Funding Source - FDA Office of Orphan Products Development
NCT01095731 ↗	The Effects of Tiopronin on 3-Aminopropanal Level & Neurologic Outcome After Aneurysmal Subarachnoid Hemorrhage	Completed	E. Sander Connolly	Phase 2	2010-04-01	The purpose of this phase II study is to further assess the safety of tiopronin in aneurysmal subarachnoid hemorrhage(aSAH) patients in order to obtain preliminary data on the efficacy of tiopronin versus placebo in reducing serum and cerebrospinal fluid (CSF) 3AP levels in this patient population. Funding Source - FDA Office of Orphan Products Development
NCT02125721 ↗	Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 4	2012-06-01	The purpose of this study is to evaluate the effect of escalating doses of cystine biding thiol drugs, including tiopronin and d-penicillamine, on the urinary cystine capacity, which is a measure of the amount of cystine in the urine, in patients with cystinuria. The overall goal will be to help guide therapy and ultimately minimize unnecessary side effects caused by larger doses.
NCT02125721 ↗	Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria	Completed	New York University School of Medicine	Phase 4	2012-06-01	The purpose of this study is to evaluate the effect of escalating doses of cystine biding thiol drugs, including tiopronin and d-penicillamine, on the urinary cystine capacity, which is a measure of the amount of cystine in the urine, in patients with cystinuria. The overall goal will be to help guide therapy and ultimately minimize unnecessary side effects caused by larger doses.

Clinical Trial Conditions for tiopronin

Condition Name

Condition Name for tiopronin
Intervention	Trials
Cystinuria	3
Aneurysmal Subarachnoid Hemorrhage	1
Drug-Induced Liver Injury	1

Condition MeSH

Condition MeSH for tiopronin
Intervention	Trials
Cystinuria	3
Drug-Induced Liver Injury	1
Chemical and Drug Induced Liver Injury	1
Subarachnoid Hemorrhage	1

Clinical Trial Locations for tiopronin

Trials by Country

Trials by Country for tiopronin
Location	Trials
United States	10
China	4

Trials by US State

Trials by US State for tiopronin
Location	Trials
New York	4
Wisconsin	1
Rhode Island	1
Massachusetts	1
Alabama	1

Clinical Trial Progress for tiopronin

Clinical Trial Phase

Clinical Trial Phase for tiopronin
Clinical Trial Phase	Trials
Phase 4	1
Phase 2	4

Clinical Trial Status

Clinical Trial Status for tiopronin
Clinical Trial Phase	Trials
Completed	4
Unknown status	1

Clinical Trial Sponsors for tiopronin

Sponsor Name

Sponsor Name for tiopronin
Sponsor	Trials
New York University School of Medicine	2
NYU Langone Health	2
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	1

Sponsor Type

Sponsor Type for tiopronin
Sponsor	Trials
Other	7
Industry	2
NIH	1